Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers
Identificadores
Identificadores
Fecha de publicación
2013Título de revista
BMC Neurology
Tipo de contenido
Artigo